October 2017

Executive Summary: The Transition from Data Aggregation to Prescriptive Analytics The global biopharmaceutical industry operates within an environment of unprecedented

Introduction In the global landscape of medicine, a pharmaceutical drug’s nonproprietary name is far more than a simple identifier. It

I. Executive Summary The global biosimilar market is undergoing a period of significant expansion, with projections indicating a robust growth

I. Executive Summary The question of whether drug companies can “bribe” the U.S. Food and Drug Administration (FDA) is often

Introduction: Navigating the High-Stakes Arena of Drug Patent Litigation In the dynamic and fiercely competitive pharmaceutical landscape, intellectual property is

I. Executive Summary The landscape of drug lifecycle management is fundamentally shaped by the intricate and evolving nature of patent

The pharmaceutical landscape is a dynamic realm, continually evolving with groundbreaking discoveries and innovative therapies. At the heart of this

In the high-stakes world of pharmaceuticals, the rules of the game seem straightforward. A company invests billions of dollars and